Brain scans of people under the influence of the psilocybin, the active ingredient in magic mushrooms, have given scientists the...
Researchers discover a low dose of psilocybin erased conditioned fear responses in mice. They suggest the agent could be a potential treatment for PTSD and related conditions.
A new study reports psilocybin influences the amygdala, weakening the processing of negative stimuli. Researchers hope the finding could pave the way for new treatment approaches for some psychiatric disorders.
The brain displays a similar pattern of activity during dreaming as it does during a psychedelic trip, a new study reports.
According to a new study, psychedelics show some success in treating some psychological disorders.
Study suggests that a single dose of psilocybin, the active ingredient of magic mushrooms, may be enough to produce a lasting decrease in depression and anxiety for cancer patients.
In a new study, researchers report on the potential for using psilocybin, a hallucinogenic compound derived from magic mushrooms, for treating patients with treatment resistant depression.
According to researchers, a single large dose if psilocybin, the active hallucinogenic compound found in magic mushrooms, helped provide relief for people suffering from cancer related depression and anxiety for up to six months.
While many people reported a 'bad trip' when taking psilocybin containing mushrooms, most report experiencing meaningful and worthwhile experiences while under the influence.
Researchers observe a sustained increase in neural signal diversity in people under the influence of psychedelics.
Used in a controlled psychotherapy setting, psychedelics have the potential to treat psychiatric treatments that do not respond to conventional medications, researchers argue.
A new study in Neuroscience of Consciousness adds weight to previous findings about the potential benefits psychedelics could have for treating mental health disorders.
